• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Haegarda

Marketing

New HAE drugs from Takeda, BioCryst are gaining popularity

Orladeyo’s growth will mainly come at the expense of CSL’s Berinert and Haegarda, while Takeda’s Takhzyro will also gain share, one analyst says.
Angus Liu Mar 18, 2022 11:16am

ICER is urging steep discounts on Takeda and CSL drugs

Aug 24, 2021 2:18pm

Can durability data keep Takeda's Takhzyro in control in HAE?

Jul 12, 2021 12:59pm

CSL sues former exec for trade secrets theft

Oct 17, 2019 11:13am

Want to thrive, pharma? Forget 'me-too' drugs, CSL chief says

Jan 14, 2019 11:18am

Shire eyes blockbuster sales with new HAE drug Takhzyro

Aug 24, 2018 11:11am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy